(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 13.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Heron Therapeutics's revenue in 2025 is $148,518,000.On average, 2 Wall Street analysts forecast HRTX's revenue for 2025 to be $23,596,254,453, with the lowest HRTX revenue forecast at $23,346,812,911, and the highest HRTX revenue forecast at $23,845,695,994. On average, 1 Wall Street analysts forecast HRTX's revenue for 2026 to be $26,073,125,051, with the lowest HRTX revenue forecast at $26,073,125,051, and the highest HRTX revenue forecast at $26,073,125,051.
In 2027, HRTX is forecast to generate $33,930,152,202 in revenue, with the lowest revenue forecast at $33,930,152,202 and the highest revenue forecast at $33,930,152,202.